MatthewJoshuaFrankMD

Clinical Fellow in Medicine, Beth Israel Deaconess Medical Center

Dr. Frank is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology and Medical Oncology, 2015 - 2018
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2011 - 2014
David Geffen School of Medicine at UCLAClass of 2011

PubMed

Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease.
Everett Meyer, Anna Pavlova, Alejandro Villar-Prados, Cameron S Bader, Bryan Xie
Blood. 2025-01-10
Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL.
Yi-Jiun Su, Anne Marijn Kramer, Mark P Hamilton, Neha Agarwal, Hrishikesh K Srinagesh
Cancer Discovery. 2025-01-07
Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice.
Michelle M Chin, John S Tamaresis, Laura J Johnston, Robert Lowsky, Everett Meyer
Bone Marrow Transplantation. 2024-11-18

Abstracts/Posters

Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel
Matthew J. Frank, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)
Matthew J. Frank, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma
Matthew J. Frank, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy
Matthew J. Frank, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis.
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and N...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018